XSHG
600010
Market cap13bUSD
Jul 09, Last price
2.09CNY
1D
-4.57%
1Q
-26.15%
Jan 2017
4.87%
IPO
-69.22%
Name
Inner Mongolia BaoTou Steel Union Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Qingdao Haier Biomedical Co., Ltd. specializes in the global development, production, sales, and distribution of low-temperature storage solutions for critical biomedical samples. Their extensive product portfolio includes a range of freezers—such as cryogenic, ultra-low temperature, biomedical, spark-free, vaccine, and plasma models—along with refrigerators designed for laboratories, pharmacies, blood banks, and vaccine storage. They also provide blood/fluid warming cabinets, essential backup systems, consumables, and specialized cold/freezer rooms, alongside comprehensive vaccine safety solutions and plasma apheresis systems. Beyond storage, the company delivers various healthcare innovations, including intelligent mobile inoculation clinics, refrigerated vaccine transport vehicles, advanced vaccine shelters, P2+ mobile nucleic acid testing vehicles, smart autonomous disinfection units, and air purification sterilizers. Their offerings further extend to medical diagnostic and support tools like infrared thermometers, blood pressure monitors, and oxygen concentrators, as well as biosafety screening booths, solar-powered medical laboratories, mobile PCR testing labs, and versatile mobile container clinics. Complementing these, they supply a selection of general laboratory equipment and transport coolers. Established in 2005, Qingdao Haier Biomedical Co., Ltd. is headquartered in Qingdao, China. Separately, Inner Mongolia Baotou Steel Union Co., Ltd. operates as a subsidiary of Baotou Iron and Steel (Group) Co., Ltd.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||